Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
$95.61
-2.3%
$81.75
$4.77
$98.64
$7.61B0.391.05 million shs789,286 shs
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$3.41
-0.3%
$2.42
$0.40
$3.51
$564M2.274.76 million shs2.13 million shs
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
$4.06
+13.1%
$3.01
$0.91
$4.54
$322.81M2.183.32 million shs4.85 million shs
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$22.20
+3.6%
$19.42
$10.41
$138.81
$2.09B0.516.42 million shs3.47 million shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
+2.29%+12.42%+16.44%+890.08%+925.37%
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
+0.59%+2.70%+71.00%+43.10%+213.76%
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
+0.84%-8.65%+33.46%+26.41%+10.80%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
-2.41%-7.31%+23.23%+16.59%-82.77%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
$95.61
-2.3%
$81.75
$4.77
$98.64
$7.61B0.391.05 million shs789,286 shs
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$3.41
-0.3%
$2.42
$0.40
$3.51
$564M2.274.76 million shs2.13 million shs
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
$4.06
+13.1%
$3.01
$0.91
$4.54
$322.81M2.183.32 million shs4.85 million shs
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$22.20
+3.6%
$19.42
$10.41
$138.81
$2.09B0.516.42 million shs3.47 million shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
+2.29%+12.42%+16.44%+890.08%+925.37%
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
+0.59%+2.70%+71.00%+43.10%+213.76%
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
+0.84%-8.65%+33.46%+26.41%+10.80%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
-2.41%-7.31%+23.23%+16.59%-82.77%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
2.91
Moderate Buy$114.2519.50% Upside
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
3.00
Buy$5.4258.85% Upside
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
2.14
Hold$5.1025.62% Upside
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
2.03
Hold$34.4255.03% Upside

Current Analyst Ratings Breakdown

Latest SRPT, CTMX, EDIT, and ABVX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/14/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/13/2025
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$142.00
10/13/2025
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$142.00
10/10/2025
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$101.00 ➝ $150.00
10/8/2025
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/8/2025
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D+)Hold (C-)
10/8/2025
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
10/8/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetSector Perform$14.00 ➝ $16.00
10/6/2025
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$112.00 ➝ $120.00
9/27/2025
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/27/2025
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D+)
(Data available from 10/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/AN/AN/AN/A$0.69 per shareN/A
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$138.10M4.07$0.36 per share9.45($0.01) per share-341.00
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
$32.31M11.30N/AN/A$1.63 per share2.49
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$1.90B1.14$2.52 per share8.80$15.99 per share1.39
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
-$190.71MN/A0.00N/AN/AN/AN/AN/AN/A
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$31.87M$0.566.09N/AN/A34.04%158.70%36.04%11/6/2025 (Estimated)
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
-$237.09M-$2.85N/AN/AN/A-608.88%-200.25%-68.57%11/3/2025 (Estimated)
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$235.24M-$0.87N/A2.03N/A-2.34%-1.03%-0.37%11/5/2025 (Estimated)

Latest SRPT, CTMX, EDIT, and ABVX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/6/2025Q3 2025
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
-$0.04N/AN/AN/A$11.50 millionN/A
11/5/2025Q3 2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$0.02N/AN/AN/A$331.51 millionN/A
11/3/2025Q3 2025
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
-$0.38N/AN/AN/AN/AN/A
9/8/2025Q2 2025
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
-$0.90-$0.86+$0.04-$0.86$1.35 millionN/A
8/12/2025Q2 2025
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
-$0.41-$0.63-$0.22-$0.63$1.81 million$3.58 million
8/6/2025Q2 2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$0.89$2.02+$1.13$1.89$530.66 million$611.09 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/AN/AN/AN/AN/A
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
N/AN/AN/AN/AN/A
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
N/AN/AN/AN/AN/A
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/A
0.77
0.77
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
N/A
4.20
4.20
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
N/A
2.77
2.77
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
0.84
2.89
1.81

Institutional Ownership

CompanyInstitutional Ownership
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
47.91%
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
67.77%
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
71.90%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
86.68%

Insider Ownership

CompanyInsider Ownership
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/A
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
6.60%
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
2.10%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
7.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
6177.83 millionN/ANot Optionable
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
170164.91 million154.03 millionOptionable
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
23089.92 million88.03 millionOptionable
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
1,37297.71 million90.29 millionOptionable

Recent News About These Companies

Sarepta Therapeutics (SRPT) Receives a Buy from Jefferies
What's Going On Sarepta Stock On Wednesday?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Abivax stock logo

Abivax NASDAQ:ABVX

$95.61 -2.21 (-2.26%)
Closing price 04:00 PM Eastern
Extended Trading
$95.75 +0.14 (+0.15%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

CytomX Therapeutics stock logo

CytomX Therapeutics NASDAQ:CTMX

$3.41 -0.01 (-0.29%)
Closing price 04:00 PM Eastern
Extended Trading
$3.46 +0.05 (+1.47%)
As of 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Editas Medicine stock logo

Editas Medicine NASDAQ:EDIT

$4.06 +0.47 (+13.09%)
Closing price 04:00 PM Eastern
Extended Trading
$4.10 +0.04 (+1.01%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Sarepta Therapeutics stock logo

Sarepta Therapeutics NASDAQ:SRPT

$22.20 +0.77 (+3.59%)
Closing price 04:00 PM Eastern
Extended Trading
$22.28 +0.08 (+0.36%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.